Nieuwenhuizen W
Gaubius Laboratory, TNO Prevention and Health, P.O. Box 2215, 2301 CE Leiden, The Netherlands.
Ann N Y Acad Sci. 2001;936:237-46. doi: 10.1111/j.1749-6632.2001.tb03512.x.
Fibrin, but not fibrinogen, enhances the rate of activation of plasminogen by tissue type plasminogen activator (t-PA). Studies with enzymatic and chemical fragments of fibrinogen showed that several sites in fibrinogen are involved in this rate enhancement; these are, A alpha 148-160 (located in CNBr fragment FCB-2), and FCB-5 (a CNBr fragment comprising gamma 312-324), and recently discovered sites in the fibrinogen alpha C domains. All these sites are buried in fibrinogen, but exposed in fibrin and some fibrinogen fragments. For the first two of these, located in the D-domains, this was shown by the fact that monoclonal antibodies against A alpha 148-160 and gamma 312-324 bind to fibrin and rate enhancing fibrin(ogen) fragments, but not to fibrinogen. Direct binding studies indicate that at physiological concentrations plasminogen binds to FCB-2, and t-PA to FCB-5. More detailed studies have demonstrated the importance of residues A alpha-157 and A alpha-152, and that the minimum stretch with rate enhancing properties is A alpha 154-159. The sites in the alpha C domains await further identification. With the recently reported three-dimensional structure of fragments D and D-dimer it is now possible to explain these findings at the molecular level. Molecular calculations and experimental data show that the site A alpha 148-160 in fibrinogen is covered among others by a part of the A alpha chain (A alpha 166-195) that forms an alpha-helix, and by a globular domain formed by the beta-chain. On fibrin formation, the last two may move away, and give access to A alpha 148-160. It is conceivable that in the alpha C domain sites are involved in the early phases of fibrinolysis. The site A alpha 148-160 and that in FCB-5 may be more important at later stages. It is also clear that fibrin polymerization is important. This polymerization has probably several effects: exposure of the rate enhancing sites; mutual positioning of the t-PA and plasminogen binding sites; a concentrating effect of t-PA and plasminogen on the fibrin surface; effects on the kinetic properties of t-PA and plasminogen. These effects together explain the rate enhancement.
纤维蛋白而非纤维蛋白原可增强组织型纤溶酶原激活剂(t-PA)激活纤溶酶原的速率。对纤维蛋白原的酶解片段和化学片段的研究表明,纤维蛋白原中的几个位点参与了这种速率增强;这些位点是Aα148 - 160(位于CNBr片段FCB - 2中)、FCB - 5(一个包含γ312 - 324的CNBr片段)以及最近在纤维蛋白原αC结构域中发现的位点。所有这些位点在纤维蛋白原中是被掩埋的,但在纤维蛋白和一些纤维蛋白原片段中是暴露的。对于位于D结构域的前两个位点,针对Aα148 - 160和γ312 - 324的单克隆抗体与纤维蛋白和具有速率增强作用的纤维蛋白(原)片段结合,但不与纤维蛋白原结合,这一事实证明了这一点。直接结合研究表明,在生理浓度下,纤溶酶原与FCB - 2结合,t-PA与FCB - 5结合。更详细的研究表明了Aα - 157和Aα - 152残基的重要性,并且具有速率增强特性的最小片段是Aα154 - 159。αC结构域中的位点有待进一步鉴定。随着最近报道的D片段和D - 二聚体的三维结构,现在有可能在分子水平上解释这些发现。分子计算和实验数据表明,纤维蛋白原中的Aα148 - 160位点被形成α - 螺旋的Aα链的一部分(Aα166 - 195)以及由β链形成的球状结构域覆盖。在纤维蛋白形成时,后两者可能会移开,从而使Aα148 - 160得以暴露。可以想象,αC结构域中的位点参与了纤维蛋白溶解的早期阶段。Aα148 - 160位点和FCB - 5中的位点在后期可能更重要。同样明显的是,纤维蛋白聚合很重要。这种聚合可能有多种作用:速率增强位点的暴露;t-PA和纤溶酶原结合位点的相互定位;t-PA和纤溶酶原在纤维蛋白表面的浓缩作用;对t-PA和纤溶酶原动力学特性的影响。这些作用共同解释了速率的增强。